Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim Bridging Study for Adult SAA/vSAA
NCT05323617Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of romiplostim in aplastic anemia, sponsored by Amgen. Planned start Aug 2023; status: withdrawn.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05323617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323617.